Tag Archives: industry trends

Big Ventures

It is rare to see triple digit millions in private financing rounds, but it does happen once or twice a year on average. In the headlines last week, was the largest triple digit VC round in years – the $160M in venture capital funding for Intarcia. With the simultaneous debt financing of $50M, the total funding round was $210M. Behind the deal were existing investors New Enterprise Associates, New Leaf Venture Partners and Venrock, plus Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

The Good, the Bad, and the Ugly for Biotech IPOs

2012-11-12-Technology-vs-HC-IPOs-btn

The troubles in the biotech IPO market are complicated to explain to industry outsiders. They read about new biotechs debuting on the public market, but also hear bankers, VCs, and CEOs complaining about how the IPO window never really opened after 2008. The reality is that we are seeing positive developments and negative trends simultaneously. On the bright side, the cumulative number of IPOs is holding up. The recent pace of biotech IPOs mimics what Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Investor Forum: The New Kids on the Biotech Block

desert

Where should biotech start-ups look for funding in the venture capital desert that is becoming the new normal? The panel The New Kids on the Biotech Block: Trends in Early-Stage Financing kicked off the 11th Annual BIO Investor Forum and focused on non-traditional early-stage investors and deal structures. Moderated by Jeron Eaves, a senior practice executive with Campbell Alliance, the panel highlighted companies that have secured financing from creative sources, like patient advocacy groups and venture Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

How does the NBI perform in the last quarter of the year?

YTD-10-08-2012

Does the NASDAQ Biotech Index (NBI) outperform the broader market in the last three months of the year, or underperform? The NBI tends to be up in the 4th quarter, but a lot of that has to do with the overall market, not the biotechs. Here are the returns for the last quarter of the year for the last 20 years: (source: Factset) When looking directly at overall performance, biotech and the broader market have had good Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Does Biotech History Repeat?

IPO-windows-btn

According to Mark Twain, “History does not repeat itself, but it does rhyme”. Little did he know that one day that would hold true for something called “Biotech”. Indeed, there seems to be a lot of rhyming going on with Biotech IPOs today with recent history. When we compare the accumulated number of IPOs in the last IPO window (2003-2007) with the current window (2009-now), we see an amazing overlay. Not identical, but not too far from it. Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,